Cranioplasty, Ventriculoperitoneal Shunt (VPS)
Conditions
Keywords
Ventriculoperitoneal Shunt, cranioplasty, Postoperative Complications, Hydrocephalus
Brief summary
The purpose of this prospective, multi-center randomized controlled trail is to compare the safety and efficacy of sequential surgery or staged surgery in patients with skull defect and hydrocephalus. The main observation will be the occurrence of complications such as postoperative infection, reoperation, shunt tube obstruction, hematoma, and subdural effusion. This will provide high-quality evidence for clinical selection of appropriate strategies.The concurrent surgery group needs to complete the VPS and CP in the same operation, and the sequence of the surgeries is determined based on the patient's condition and is recorded.However, the staged surgery group requires two surgeries, with an interval of 2 to 8 weeks and the operation order is determined by randomization.Within 1 week after surgery, participants should cooperate to monitor vital signs, assess neurological function ( such as GCS、GOS, etc.), conduct head CT examinations regularly to observe the postoperative intracranial condition, and record the occurrence of postoperative complications.Postoperative follow-up should last for at least 6 months.Outpatient or telephone follow-ups should be conducted at 1 week, 1 month, 3 months, and 6 months after the surgery.During each follow-up, a neurological function assessment and quality of life score (such as the SF-36 Health Survey) should be completed, and the occurrence of postoperative complications should be recorded.
Detailed description
Study Design and Setting This study is a prospective, multi-center randomized controlled trail and partly conducted in the First Affiliated Hospital of USTC in China.Patients especially who have following conditions:(1、having a history of prior CP or VPS. surgical.2、requiring bilateral CP.3、unsuitable for simulataneous surgery) will be recruited to the study.Before the operation, patients and their family member will be fully informed of the surgical risks. Evaluation Endpoints Efficacy Endpoints:1. Neurological functional recovery: Assessed using the modified Rankin Scale (mRS) and Glasgow Coma Scale (GCS). Improvement is defined as a reduction in mRS score of ≥1 point or an increase in GCS score of ≥2 points at 12 months postoperatively. 2\. Change in ventricular size: Postoperative cranial CT at 6 months showing a ≥20% reduction in the width of the lateral ventricular body compared to preoperative measurements. Safety Endpoints1. Subdural effusion: Incidence of subdural fluid collection \>1 cm in thickness with mass effect, as shown on CT scan at 1 month postoperatively. 2\. Infection: Incidence of overall infection, central nervous system infection, cranioplasty site infection, and shunt infection. 3\. Shunt obstruction: Incidence of shunt obstruction requiring surgical revision within 6 months postoperatively. 4\. Hematoma: Incidence of epidural/subdural hematoma or intracranial hematoma requiring intervention. 5\. Reoperation rate: Proportion of patients requiring secondary surgery due to complications within 1 year postoperatively.
Interventions
Randomization of patients with the time of choosing VPS and VP
Sponsors
Study design
Eligibility
Inclusion criteria
* 1.Patients who have undergone decompressive craniectomy (DC) for conditions such as Traumatic Brain Injury (TBI), Intracerebral Hemorrhage (ICH), Subarachnoid Hemorrhage (SAH), or Ischemic Stroke (IS), and present with a skull defect concurrent with hydrocephalus. Hydrocephalus must be confirmed by cranial CT/MRI and cerebrospinal fluid pressure measurement. 2.A definitive diagnosis of hydrocephalus must meet the following criterion: presence of ventriculomegaly (Evans Index \> 0.3), accompanied by either elevated intracranial pressure (or high bone flap pressure) OR clinical symptoms such as headache, vomiting, or impaired consciousness. 3.Baseline characteristics: Age between 18 and 70 years, any gender, stable vital signs, and medically fit to tolerate surgery. 4.Informed consent: The patient or their legal guardian must provide written informed consent.
Exclusion criteria
1. Patients with a history of prior cranioplasty (CP) or ventriculoperitoneal shunt (VPS) surgery (i.e., re-operation cases). 2. Patients requiring bilateral cranioplasty. 3. Patients deemed unsuitable for simultaneous surgery, such as those with excessively bulging or tense bone flaps that preclude safe cranioplasty. 4. Patients with severe organ failure, coagulation dysfunction, or other systemic conditions that render them unable to tolerate major surgery. 5. Patients with active intracranial infection, abdominal infection, or systemic infection during the acute phase. 6. Patients with a known allergy or hypersensitivity to the surgical materials used (e.g., PEEK implants, shunt components). 7. Pregnant or lactating women. 8. Patients unable or unwilling to comply with the required follow-up schedule. -
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Overall Complication Rate | within 1year postoperatively | A composite outcome measuring the occurrence of any of the following postoperative complications within 1 year: 1. Infections (overall, central nervous system, cranioplasty site, shunt-related) 2. Reoperation due to complications (e.g., infection, shunt obstruction) 3. Shunt obstruction requiring intervention 4. Hematoma (epidural, subdural, intracranial) requiring intervention 5. Subdural effusion with clinical symptoms Unit of Measure: Proportion of participants with at least one complication(%) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Functional Independence measured by modified Rankin Scale (mRS) | within 12 months postoperatively | Assessment of global disability and functional outcome using the modified Rankin Scale. The mRS is a 7-point scale ranging from 0 (no symptoms) to 6 (death). Higher scores indicate worse outcomes (greater disability). |
| Level of Consciousness measured by Glasgow Coma Scale (GCS) | within 12 months postoperatively | Assessment of neurological status and consciousness level using the Glasgow Coma Scale. The GCS is a 15-point scale (range 3-15) evaluating eye, verbal, and motor responses. Higher scores indicate better neurological function. |
| Quality of Life measured by 36-Item Short Form Survey (SF-36) | 6 months postoperatively | Assessment of health-related quality of life using the 36-Item Short Form Survey (SF-36). The SF-36 is a 36-item questionnaire that yields eight scaled scores, each ranging from 0 to 100, with higher scores indicating better health-related quality of life. Scale Info: Each of the eight domains is scored from 0 to 100, with higher scores representing a better quality of life. |
| Total Operative Time | intraoperative | Duration of the surgical procedure from incision to closure. Unit of Measures:minutes |
| Intraoperative Blood Loss | intraoperative | Estimated volume of blood lost during the surgical procedure. Unit of Measure: milliliters (ML) |
| Total Medical Costs | during the postoperative hospitalization period, up to 30 days | Total direct medical costs incurred during the hospitalization for the surgery (including costs for both surgeries in the staged group). Unit of Measure: cost in local currency (e.g., CNY) |
| Total Length of Hospital Stay | during the postoperative hospitalization period, up to 30 days | Total number of days from admission to discharge after the index surgery (or after the second surgery in the staged group). Unit of Measure: days |
Countries
China
Contacts
The First Affiliated Hospital of University of Science and Technology of China